In September 2017, two weeks after Hurricane Irma pummeled South Georgia, Angela Ammons found her hospital on life support. It was her first day as CEO of Clinch Memorial Hospital. As she walked the halls, past oversized framed photos of the nearby Okefenokee Swamp, she felt relieved that the hurricane had spared the facility, but … Read more
As a third wave of COVID-19 sweeps across the United States, the country has reached another devastating milestone: more than 10 million people have tested positive for coronavirus, according to Johns Hopkins University numbers as of 2 p.m. E.T. on Monday. A million cases of the virus have been reported in the last 10 days … Read more
On Nov. 9, the Biden-Harris transition team announced the members of its COVID-19 advisory board, and met with them for several hours in a virtual conference before President-elect Joe Biden made remarks stressing the importance of mask wearing as a continued “weapon” in the fight against COVID-19. “As we work toward a safe and effective … Read more
Pharmaceutical giant Pfizer has announced that its COVID-19 vaccine successfully prevented 90% of disease compared to a placebo, a more positive result than experts expected. The analysis is based on 94 cases of infection with SARS-CoV-2, the virus that causes COVID-19, among both the vaccinated and placebo groups. Experts had set a minimum threshold of … Read more
The news Monday that Pfizer’s coronavirus vaccine is more than 90 percent effective sharply increased prospects that federal regulators will authorize the vaccine on an emergency basis as early as mid-December, and that the first shots will be administered before the end of the year or early next year. View original article Contributor: Laurie McGinley
Pfizer and its German partner, BioNTech, say they will apply for emergency authorization from regulators after the third week of November. View original article Contributor: Carolyn Y. Johnson
Health experts have championed the medicine as a powerful tool to change the course of the pandemic and work as a bridge to a vaccine. But the initial scarcity of the drug and the logistical complexities of administering it could mute its immediate impact on the pandemic. View original article Contributor: Carolyn Y. Johnson
The news Monday that Pfizer’s coronavirus vaccine is more than 90 percent effective sharply increased prospects that federal regulators will authorize the vaccine on an emergency basis as early as mid-December, and that the first shots will be administered before the end of the year or early next year. View original article Contributor: Laurie McGinley
Pfizer and its German partner, BioNTech, say they will apply for emergency authorization from regulators after the third week of November. View original article Contributor: Carolyn Y. Johnson
Health experts have championed the medicine as a powerful tool to change the course of the pandemic and work as a bridge to a vaccine. But the initial scarcity of the drug and the logistical complexities of administering it could mute its immediate impact on the pandemic. View original article Contributor: Carolyn Y. Johnson